{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:31:21Z","timestamp":1772591481009,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"38","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1038\/s41388-018-0299-8","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T09:07:17Z","timestamp":1527671237000},"page":"5221-5232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL"],"prefix":"10.1038","volume":"37","author":[{"given":"Marilynn","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"MacManiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent T.","family":"Bicocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bill H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshi J.","family":"Alumkal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"key":"299_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1046\/j.1365-2141.2003.04113.x","volume":"120","author":"R Foa","year":"2003","unstructured":"Foa R, Vitale A, Mancini M, Cuneo A, Mecucci C, Elia L, et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol. 2003;120:484\u20137.","journal-title":"Br J Haematol"},{"key":"299_CR2","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1158\/1078-0432.CCR-11-1936","volume":"18","author":"ML Loh","year":"2012","unstructured":"Loh ML, Mullighan CG. Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy. Clin Cancer Res. 2012;18:2754\u201367.","journal-title":"Clin Cancer Res"},{"key":"299_CR3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjh.14474","volume":"176","author":"SK Tasian","year":"2017","unstructured":"Tasian SK, Hunger SP. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics. Br J Haematol. 2017;176:867\u201382.","journal-title":"Br J Haematol"},{"key":"299_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/blood-2009-07-232124","volume":"115","author":"AV Moorman","year":"2010","unstructured":"Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115:206\u201314.","journal-title":"Blood"},{"key":"299_CR5","doi-asserted-by":"publisher","first-page":"11464","DOI":"10.1073\/pnas.96.20.11464","volume":"96","author":"JR McWhirter","year":"1999","unstructured":"McWhirter JR, Neuteboom ST, Wancewicz EV, Monia BP, Downing JR, Murre C. Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. Proc Natl Acad Sci USA. 1999;96:11464\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"299_CR6","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1038\/sj.onc.1208568","volume":"24","author":"J Mazieres","year":"2005","unstructured":"Mazieres J, You L, He B, Xu Z, Lee AY, Mikami I, et al. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene. 2005;24:5396\u2013400.","journal-title":"Oncogene"},{"key":"299_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.exphem.2008.10.007","volume":"37","author":"MK Nygren","year":"2009","unstructured":"Nygren MK, Dosen-Dahl G, Stubberud H, Walchli S, Munthe E, Rian E. beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells. Exp Hematol. 2009;37:225\u201333.","journal-title":"Exp Hematol"},{"key":"299_CR8","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V87.4.1211.bloodjournal8741211","volume":"87","author":"SP Hunger","year":"1996","unstructured":"Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood. 1996;87:1211\u201324.","journal-title":"Blood"},{"key":"299_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162638","volume":"11","author":"D Chen","year":"2016","unstructured":"Chen D, Zheng J, Gerasimcik N, Lagerstedt K, Sjogren H, Abrahamsson J, et al. The expression pattern of the Pre-B cell receptor components correlates with cellular stage and clinical outcome in acute lymphoblastic leukemia. PloS One. 2016;11:e0162638.","journal-title":"PloS One"},{"key":"299_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccr.2012.08.027","volume":"22","author":"VT Bicocca","year":"2012","unstructured":"Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 2012;22:656\u201367.","journal-title":"Cancer Cell"},{"key":"299_CR11","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1084\/jem.20042101","volume":"201","author":"N Feldhahn","year":"2005","unstructured":"Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, Wartenberg M, et al. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med. 2005;201:1837\u201352.","journal-title":"J Exp Med"},{"key":"299_CR12","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1073\/pnas.0712148105","volume":"105","author":"T Fukuda","year":"2008","unstructured":"Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA. 2008;105:3047\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"key":"299_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1073\/pnas.1308374111","volume":"111","author":"GF Widhopf 2nd","year":"2014","unstructured":"Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z, et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice. Proc Natl Acad Sci USA. 2014;111:793\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"299_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1158\/1078-0432.CCR-07-1823","volume":"14","author":"S Baskar","year":"2008","unstructured":"Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008;14:396\u2013404.","journal-title":"Clin Cancer Res"},{"key":"299_CR15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/ijc.23587","volume":"123","author":"AH Daneshmanesh","year":"2008","unstructured":"Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer. 2008;123:1190\u20135.","journal-title":"Int J Cancer"},{"key":"299_CR16","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1080\/10428190802124000","volume":"49","author":"M Shabani","year":"2008","unstructured":"Shabani M, Asgarian-Omran H, Vossough P, Sharifian RA, Faranoush M, Ghragozlou S, et al. Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms\u2019 tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2008;49:1360\u20137.","journal-title":"Leuk Lymphoma"},{"key":"299_CR17","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.leukres.2011.06.021","volume":"35","author":"HE Broome","year":"2011","unstructured":"Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res. 2011;35:1390\u20134.","journal-title":"Leuk Res"},{"key":"299_CR18","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","volume":"181","author":"S Zhang","year":"2012","unstructured":"Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012;181:1903\u201310.","journal-title":"Am J Pathol"},{"key":"299_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031127","volume":"7","author":"S Zhang","year":"2012","unstructured":"Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012;7:e31127.","journal-title":"PLoS One"},{"key":"299_CR20","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","volume":"23","author":"A Balakrishnan","year":"2017","unstructured":"Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, et al. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clin Cancer Res. 2017;23:3061\u201371.","journal-title":"Clin Cancer Res"},{"key":"299_CR21","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","volume":"116","author":"M Hudecek","year":"2010","unstructured":"Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010;116:4532\u201341.","journal-title":"Blood"},{"key":"299_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4161\/mabs.19870","volume":"4","author":"S Baskar","year":"2012","unstructured":"Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C. Targeting malignant B cells with an immunotoxin against ROR1. MAbs. 2012;4:349\u201361.","journal-title":"MAbs"},{"key":"299_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/leu.2014.199","volume":"29","author":"R Mani","year":"2015","unstructured":"Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, et al. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia. 2015;29:346\u201355.","journal-title":"Leukemia"},{"key":"299_CR24","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1016\/j.clml.2015.02.010","volume":"15","author":"MY Choi","year":"2015","unstructured":"Choi MY, Widhopf GF 2nd, Wu CC, Cui B, Lao F, Sadarangani A, et al. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015;15:S167\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"299_CR25","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1158\/0008-5472.CAN-10-2662","volume":"71","author":"A Gentile","year":"2011","unstructured":"Gentile A, Lazzari L,Benvenuti S,Trusolino L,Comoglio PM. Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis. Cancer Research. 2011;71:3132\u201341.","journal-title":"Cancer Research"},{"key":"299_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011859","volume":"5","author":"P Li","year":"2010","unstructured":"Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One. 2010;5:e11859.","journal-title":"PLoS One"},{"key":"299_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ccr.2012.02.008","volume":"21","author":"T Yamaguchi","year":"2012","unstructured":"Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, et al. NKX2-1\/TITF1\/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012;21:348\u201361.","journal-title":"Cancer Cell"},{"key":"299_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1748-1716.2011.02306.x","volume":"203","author":"M Kaucka","year":"2011","unstructured":"Kaucka M, Krejci P, Plevova K, Pavlova S, Prochazkova J, Janovska P, et al. Post-translational modifications regulate signalling by Ror1. Acta Physiol. 2011;203:351\u201362.","journal-title":"Acta Physiol"},{"key":"299_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bbrc.2015.06.104","volume":"464","author":"J Ma","year":"2015","unstructured":"Ma J, Peng J, Mo R, Ma S, Wang J, Zang L, et al. Ubiquitin E3 ligase UHRF1 regulates p53 ubiquitination and p53-dependent cell apoptosis in clear cell Renal Cell Carcinoma. Biochem Biophys Res Commun. 2015;464:147\u201353.","journal-title":"Biochem Biophys Res Commun"},{"key":"299_CR30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1128\/MCB.01598-07","volume":"28","author":"P Karagianni","year":"2008","unstructured":"Karagianni P, Amazit L, Qin J, Wong J. ICBP90, a novel methyl K9 H3 binding protein linking protein ubiquitination with heterochromatin formation. Mol Cell Biol. 2008;28:705\u201317.","journal-title":"Mol Cell Biol"},{"key":"299_CR31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/nar\/gkn961","volume":"37","author":"JK Kim","year":"2009","unstructured":"Kim JK, Esteve PO, Jacobsen SE, Pradhan S. UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucleic Acids Res. 2009;37:493\u2013505.","journal-title":"Nucleic Acids Res"},{"key":"299_CR32","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1245\/s10434-011-2194-1","volume":"19","author":"F Wang","year":"2012","unstructured":"Wang F, Yang YZ, Shi CZ, Zhang P, Moyer MP, Zhang HZ, et al. UHRF1 promotes cell growth and metastasis through repression ofp16(ink(4)a) in colorectal cancer. Ann Surg Oncol. 2012;19:2753\u201362.","journal-title":"Ann Surg Oncol"},{"key":"299_CR33","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature07249","volume":"455","author":"K Arita","year":"2008","unstructured":"Arita K, Ariyoshi M, Tochio H, Nakamura Y, Shirakawa M. Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature. 2008;455:818\u201321.","journal-title":"Nature"},{"key":"299_CR34","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nature07273","volume":"455","author":"GV Avvakumov","year":"2008","unstructured":"Avvakumov GV, Walker JR, Xue S, Li Y, Duan S, Bronner C, et al. Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature. 2008;455:822\u20135.","journal-title":"Nature"},{"key":"299_CR35","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nature06397","volume":"450","author":"J Sharif","year":"2007","unstructured":"Sharif J, Muto M, Takebayashi S, Suetake I, Iwamatsu A, Endo TA, et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature. 2007;450:908\u201312.","journal-title":"Nature"},{"key":"299_CR36","doi-asserted-by":"publisher","first-page":"7601","DOI":"10.1038\/sj.onc.1208053","volume":"23","author":"M Unoki","year":"2004","unstructured":"Unoki M, Nishidate T, Nakamura Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene. 2004;23:7601\u201310.","journal-title":"Oncogene"},{"key":"299_CR37","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1093\/nar\/gkp1152","volume":"38","author":"A Rottach","year":"2010","unstructured":"Rottach A, Frauer C, Pichler G, Bonapace IM, Spada F, Leonhardt H. The multi-domain protein Np95 connects DNA methylation and histone modification. Nucleic Acids Res. 2010;38:1796\u2013804.","journal-title":"Nucleic Acids Res"},{"key":"299_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.molcel.2011.07.006","volume":"43","author":"E Rajakumara","year":"2011","unstructured":"Rajakumara E, Wang Z, Ma H, Hu L, Chen H, Lin Y, et al. PHD finger recognition of unmodified histone H3R2 links UHRF1 to regulation of euchromatic gene expression. Mol Cell. 2011;43:275\u201384.","journal-title":"Mol Cell"},{"key":"299_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13046-016-0453-5","volume":"35","author":"M Alhosin","year":"2016","unstructured":"Alhosin M, Omran Z, Zamzami MA, Al-Malki AL, Choudhry H, Mousli M, et al. Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer. J Exp Clin Cancer Res. 2016;35:174.","journal-title":"J Exp Clin Cancer Res"},{"key":"299_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ejmech.2016.02.043","volume":"114","author":"V Myrianthopoulos","year":"2016","unstructured":"Myrianthopoulos V, Cartron PF, Liutkeviciute Z, Klimasauskas S, Matulis D, Bronner C, et al. Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation. Eur J Med Chem. 2016;114:390\u20136.","journal-title":"Eur J Med Chem"},{"key":"299_CR41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/sj.bjc.6601068","volume":"89","author":"M Mousli","year":"2003","unstructured":"Mousli M, Hopfner R, Abbady AQ, Monte D, Jeanblanc M, Oudet P, et al. ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer. 2003;89:120\u20137.","journal-title":"Br J Cancer"},{"key":"299_CR42","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/cncr.25531","volume":"117","author":"A Daskalos","year":"2011","unstructured":"Daskalos A, Oleksiewicz U, Filia A, Nikolaidis G, Xinarianos G, Gosney JR, et al. UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. Cancer. 2011;117:1027\u201337.","journal-title":"Cancer"},{"key":"299_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ccr.2014.01.003","volume":"25","author":"R Mudbhary","year":"2014","unstructured":"Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, et al. UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell. 2014;25:196\u2013209.","journal-title":"Cancer Cell"},{"key":"299_CR44","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/path.4665","volume":"238","author":"W Abu-Alainin","year":"2016","unstructured":"Abu-Alainin W, Gana T, Liloglou T, Olayanju A, Barrera LN, Ferguson R, et al. UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis. J Pathol. 2016;238:423\u201333.","journal-title":"J Pathol"},{"key":"299_CR45","doi-asserted-by":"publisher","first-page":"16007","DOI":"10.1038\/celldisc.2016.7","volume":"2","author":"Y Jia","year":"2016","unstructured":"Jia Y, Li P, Fang L, Zhu H, Xu L, Cheng H, et al. Negative regulation of DNMT3A de novo DNA methylation by frequently overexpressed UHRF family proteins as a mechanism for widespread DNA hypomethylation in cancer. Cell Discov. 2016;2:16007.","journal-title":"Cell Discov"},{"key":"299_CR46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1080\/15592294.2015.1048060","volume":"10","author":"X Qu","year":"2015","unstructured":"Qu X, Davison J, Du L, Storer B, Stirewalt DL, Heimfeld S, et al. Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia. Epigenetics. 2015;10:526\u201335.","journal-title":"Epigenetics"},{"key":"299_CR47","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood-2013-01-480244","volume":"122","author":"B Niebuhr","year":"2013","unstructured":"Niebuhr B, Kriebitzsch N, Fischer M, Behrens K, Gunther T, Alawi M, et al. Runx1 is essential at two stages of early murine B-cell development. Blood. 2013;122:413\u201323.","journal-title":"Blood"},{"key":"299_CR48","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3892\/ijo.2015.2857","volume":"46","author":"MY Kim","year":"2015","unstructured":"Kim MY, Park SJ, Shim JW, Yang K, Kang HS, Heo K. Naphthazarin enhances ionizing radiation-induced cell cycle arrest and apoptosis in human breast cancer cells. Int J Oncol. 2015;46:1659\u201366.","journal-title":"Int J Oncol"},{"key":"299_CR49","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s10495-011-0613-1","volume":"16","author":"BR Acharya","year":"2011","unstructured":"Acharya BR, Bhattacharyya S, Choudhury D, Chakrabarti G. The microtubule depolymerizing agent naphthazarin induces both apoptosis and autophagy in A549 lung cancer cells. Apoptosis. 2011;16:924\u201339.","journal-title":"Apoptosis"},{"key":"299_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3892\/ijo.2011.1288","volume":"40","author":"JA Kim","year":"2012","unstructured":"Kim JA, Lee EK, Park SJ, Kim ND, Hyun DH, Lee CG, et al. Novel anti-cancer role of naphthazarin in human gastric cancer cells. Int J Oncol. 2012;40:157\u201362.","journal-title":"Int J Oncol"},{"key":"299_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/hon.904","volume":"27","author":"R Rau","year":"2009","unstructured":"Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol. 2009;27:171\u201381.","journal-title":"Hematol Oncol"},{"key":"299_CR52","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/mc.22426","volume":"55","author":"NB Fernandez","year":"2016","unstructured":"Fernandez NB, Lorenzo D, Picco ME, Barbero G, Dergan-Dylon LS, Marks MP, et al. ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K\/Akt pathway. Mol Carcinog. 2016;55:1772\u201385.","journal-title":"Mol Carcinog"},{"key":"299_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/srep08996","volume":"5","author":"M Alhosin","year":"2015","unstructured":"Alhosin M, Leon-Gonzalez AJ, Dandache I, Lelay A, Rashid SK, Kevers C, et al. Bilberry extract (Antho 50) selectively induces redox-sensitive caspase 3-related apoptosis in chronic lymphocytic leukemia cells by targeting the Bcl-2\/Bad pathway. Sci Rep. 2015;5:8996.","journal-title":"Sci Rep"},{"key":"299_CR54","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s13238-014-0059-7","volume":"5","author":"N Borcherding","year":"2014","unstructured":"Borcherding N, Kusner D, Liu GH, Zhang W. ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell. 2014;5:496\u2013502.","journal-title":"Protein Cell"},{"key":"299_CR55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/leu.2009.217","volume":"24","author":"A Sanchez-Aguilera","year":"2010","unstructured":"Sanchez-Aguilera A, Rattmann I, Drew DZ, Muller LU, Summey V, Lucas DM, et al. Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia. Leukemia. 2010;24:97\u2013104.","journal-title":"Leukemia"},{"key":"299_CR56","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1182\/blood-2011-12-395939","volume":"119","author":"A Troeger","year":"2012","unstructured":"Troeger A, Johnson AJ, Wood J, Blum WG, Andritsos LA, Byrd JC, et al. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. Blood. 2012;119:4708\u201318.","journal-title":"Blood"},{"key":"299_CR57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.molcel.2005.12.007","volume":"21","author":"Y Doyon","year":"2006","unstructured":"Doyon Y, Cayrou C, Ullah M, Landry AJ, Cote V, Selleck W, et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell. 2006;21:51\u201364.","journal-title":"Mol Cell"},{"key":"299_CR58","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1128\/MCB.00159-10","volume":"31","author":"AJ Kueh","year":"2011","unstructured":"Kueh AJ, Dixon MP, Voss AK, Thomas T. HBO1 is required for H3K14 acetylation and normal transcriptional activity during embryonic development. Mol Cell Biol. 2011;31:845\u201360.","journal-title":"Mol Cell Biol"},{"key":"299_CR59","doi-asserted-by":"publisher","first-page":"8695","DOI":"10.1073\/pnas.0903233106","volume":"106","author":"JW Tyner","year":"2009","unstructured":"Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci USA. 2009;106:8695\u2013700.","journal-title":"Proc Natl Acad Sci USA"},{"key":"299_CR60","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1158\/2159-8290.CD-12-0504","volume":"3","author":"T Sanda","year":"2013","unstructured":"Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 2013;3:564\u201377.","journal-title":"Cancer Discov"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0299-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0299-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0299-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:11:53Z","timestamp":1684617113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0299-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":60,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["299"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0299-8","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,30]]},"assertion":[{"value":"30 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. JWT's work has received research support from Agios Pharmaceuticals, Array Biopharma, Aptose Biosciences, AstraZeneca, Constellation Pharmaceuticals, Genentech, Gilead, Incyte Corporation, Janssen Pharmaceutica, Seattle Genetics, Syros, Takeda Pharmaceutical Company and is a co-founder of Leap Oncology. All the remaining authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}